Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication

Executive Summary

Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.

Related Content

Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
PEG-Intron/Rebetol Subgroups Should Be Analyzed, Cmte. Says
PEG-Intron Access Program Requires ID Number, Designed To Ensure Supply
Schering Rebetol Costs $1,650 Per Month, 3% Less Than Combo Rebetron
Schering PEG-Intron/Rebetol Phase IV To Evaluate Alternate Dosing Regimen
Roche Pegasys
Roche Pegasys
Roche Agenda For 2001 Includes Kytril NDA For Post-Op Use, Pegasys Launch
Schering PEG-Intron Phase IV Trial To Study African Americans



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts